Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NAMS
Upturn stock ratingUpturn stock rating

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)

Upturn stock ratingUpturn stock rating
$25.17
Last Close (24-hour delay)
Profit since last BUY22.78%
upturn advisory
Strong Buy
BUY since 45 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: NAMS (3-star) is a STRONG-BUY. BUY since 45 days. Profits (22.78%). Updated daily EoD!

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

9 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $40.39

1 Year Target Price $40.39

Analysts Price Target For last 52 week
$40.39 Target price
52w Low $14.06
Current$25.17
52w High $27.29

Analysis of Past Performance

Type Stock
Historic Profit 98.35%
Avg. Invested days 41
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.83B USD
Price to earnings Ratio -
1Y Target Price 40.39
Price to earnings Ratio -
1Y Target Price 40.39
Volume (30-day avg) 9
Beta -0.01
52 Weeks Range 14.06 - 27.29
Updated Date 08/15/2025
52 Weeks Range 14.06 - 27.29
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.59

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date 2025-08-07
When Before Market
Estimate -0.44
Actual -0.15

Profitability

Profit Margin -258.91%
Operating Margin (TTM) -186.13%

Management Effectiveness

Return on Assets (TTM) -17.12%
Return on Equity (TTM) -28.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2096024287
Price to Sales(TTM) 44.29
Enterprise Value 2096024287
Price to Sales(TTM) 44.29
Enterprise Value to Revenue 32.75
Enterprise Value to EBITDA 27.63
Shares Outstanding 112628000
Shares Floating 55257774
Shares Outstanding 112628000
Shares Floating 55257774
Percent Insiders 0.39
Percent Institutions 111.74

ai summary icon Upturn AI SWOT

NewAmsterdam Pharma Company N.V. Ordinary Shares

stock logo

Company Overview

overview logo History and Background

NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on the research and development of transformative therapies for cardio-metabolic diseases with high unmet medical need. It was founded in 2019 and merged with a SPAC in 2022 to go public. Initial focus is on cholesterol reduction.

business area logo Core Business Areas

  • Lipid Metabolism Therapies: Focuses on developing therapies that modulate lipid metabolism, primarily targeting elevated LDL-C and triglyceride levels to reduce cardiovascular risk.

leadership logo Leadership and Structure

Michael Davidson, MD, is the Chief Executive Officer. The company has a board of directors with experience in the pharmaceutical industry and finance.

Top Products and Market Share

overview logo Key Offerings

  • Obicetrapib: Obicetrapib is a cholesteryl ester transfer protein (CETP) inhibitor being developed for lowering LDL-C levels. It's in Phase 3 clinical trials. Competitors include statins (e.g., atorvastatin, rosuvastatin) and PCSK9 inhibitors (e.g., evolocumab, alirocumab). Market share is currently 0% as it is still in development.

Market Dynamics

industry overview logo Industry Overview

The market for lipid-lowering therapies is large and growing, driven by the increasing prevalence of cardiovascular disease and related risk factors. The industry is competitive, with both established pharmaceutical companies and emerging biotech firms.

Positioning

NewAmsterdam Pharma aims to carve out a niche by providing a novel oral CETP inhibitor, potentially offering advantages over existing injectable PCSK9 inhibitors. Success depends on positive clinical trial results and successful commercialization.

Total Addressable Market (TAM)

The global lipid-lowering drug market is estimated at hundreds of billions of dollars. NewAmsterdam is positioned to capture a significant portion through Obicetrapib if approved and demonstrating superior efficacy and tolerability.

Upturn SWOT Analysis

Strengths

  • Novel CETP inhibitor with potential for significant LDL-C reduction
  • Oral formulation offers patient convenience over injectable PCSK9 inhibitors
  • Experienced management team
  • Focus on a large and growing market

Weaknesses

  • Development stage company with no currently marketed products
  • High reliance on the success of Obicetrapib
  • Limited financial resources compared to larger pharmaceutical companies
  • CETP inhibitors have had historical safety concerns in other drugs of the same class

Opportunities

  • Positive clinical trial results could lead to rapid regulatory approval
  • Partnerships with larger pharmaceutical companies for commercialization
  • Expansion into other cardio-metabolic indications
  • Address high unmet needs in patients not well controlled on current therapies

Threats

  • Clinical trial failures or safety concerns
  • Competition from existing and emerging therapies
  • Pricing pressures from payers
  • Regulatory hurdles

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • REGN
  • NVO
  • LLY

Competitive Landscape

NewAmsterdam Pharma faces competition from established pharmaceutical companies with marketed lipid-lowering therapies and other companies developing novel therapies. Its competitive advantage lies in the potential of Obicetrapib to offer a convenient and effective oral treatment option.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited as it is development stage.

Future Projections: Future growth depends on the successful development and commercialization of Obicetrapib and other pipeline products. Analyst estimates vary widely based on clinical trial outcomes.

Recent Initiatives: Recent initiatives include advancing Phase 3 clinical trials for Obicetrapib, exploring potential partnerships, and evaluating new targets in cardio-metabolic disease.

Summary

NewAmsterdam Pharma is a high-risk, high-reward company focused on developing Obicetrapib, a novel CETP inhibitor, for lowering LDL-C. Its success hinges on positive clinical trial data and successful commercialization. While promising, the company faces competition and regulatory hurdles. The company must continue to grow its resources and reduce spending while commercializing its products.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Financial data and market share estimates are subject to change. Consult a financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About NewAmsterdam Pharma Company N.V. Ordinary Shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2022-11-23
CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 68
Full time employees 68

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.